Skip to content
value.today
Sight Sciences, Inc. logo

Sight Sciences, Inc.

SGHT
$448 Mmarket cap on Aug 1, 2026+82.1% since Jan 2024
Compare
World rank
#13,062
Revenue
$77 M
For year ending December-2025
Net income
$-38 M
-49.7% margin
SEC filing
Employees
186
As of December 31, 2025
SEC filing

Sight Sciences, Inc. in brief

Sight Sciences, Inc. is a listed company in the Medical Devices industry, based in Menlo Park, California, USA. It was founded in 2010. Its market value was $448 M on 1 August 2026, which makes it the 13,062nd largest listed company in the world and the 2,602nd largest in the USA on this site. In the year to December 2025 it had sales of $77 M and a net loss of $38 M. It employs about 186 people and Paul Badawi is its chief executive. Its largest business segments by sales in 2025 were Interventional Glaucoma (98%) and Interventional Dry Eye (2%). Its shares trade under the symbol SGHT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Sight Sciences, Inc.

Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We are passionate about improving patients’ lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient-friendly, interventional solutions to eye care professionals; and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our technologies may be used in procedures which supplant conventional outdated approaches.

From the company's annual report filed with the US SEC: read the report

Sight Sciences, Inc. timeline

4 events, 2010–2023
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2011
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 15 July 2021; shares registered for exchange trading on 8 July 2021.
  7. 2023
  8. 💰
    Record revenue of $81 million
    FY2023, the highest of the 6 years on record.

Events of Sight Sciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$203 M$406 M$609 M$812 M2023202420252026

World rank over time

▼ down 1,683 places since 2022
2022-01-07: #11022#11,02220222022-12-25: #11446#11,44620222023-07-30: #13766#13,76620232024-01-05: #16833#16,83320242026-03-08: #8983#8,98320262026-08-01: #12705#12,7052026

Rank in USA: #2,819 (Jan 2022) · #2,463 (Dec 2022) · #2,839 (Jul 2023) · #3,091 (Jan 2024) · #1,704 (Mar 2026) · #2,600 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
5.1×
Price / book
7.0×
Free cash flow yield
-6.7%
Net margin (TTM)
-32.1%
Operating margin
-48.0%
Return on equity
-44.4%
Liabilities / assets
44.5%
Net debt
$-50M
Revenue growth
-3.1%
R&D / revenue
18.9%
Revenue per employee
$416 K
Profit per employee
$-207 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $28M, net income $-35M$28MFY20Fiscal year ending Dec 2021: revenue $49M, net income $-63M$49MFY21Fiscal year ending Dec 2022: revenue $71M, net income $-86M$71MFY22Fiscal year ending Dec 2023: revenue $81M, net income $-56M$81MFY23Fiscal year ending Dec 2024: revenue $80M, net income $-52M$80MFY24Fiscal year ending Dec 2025: revenue $77M, net income $-38M$77MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$77M-3.1%$-37M$-38M-49.7%
Dec 2024$80M-1.5%$-51M$-52M-64.5%
Dec 2023$81M+13.6%$-57M$-56M-68.5%
Dec 2022$71M+45.7%$-84M$-86M-120.9%
Dec 2021$49M+77.1%$-51M$-63M-128.6%
Dec 2020$28M—$-32M$-35M-125.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-30M$0M$-30M$-0.74—
Dec 2024$-22M$0M$-23M$-1.03—
Dec 2023$-47M$1M$-48M$-1.14—
Dec 2022$-76M$1M$-77M$-1.80—
Dec 2021$-53M$1M$-53M$-2.36—
Dec 2020$-32M$1M$-33M$-3.71—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$88M
Net income, trailing 12 months
$-28M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $19M, net income $-12M$19MDec ’24Three months to Mar 2025: revenue $18M, net income $-14M$18MMar ’25Three months to Jun 2025: revenue $20M, net income $-12M$20MJun ’25Three months to Sep 2025: revenue $20M, net income $-8M$20MSep ’25Three months to Dec 2025 (from the annual report): revenue $20M, net income $-4M$20MDec ’25Three months to Mar 2026: revenue $20M, net income $-13M$20MMar ’26Three months to Jun 2026: revenue $23M, net income $-4M$23MJun ’26Three months to Sep 2026: revenue $25M, net income $-7M$25MSep ’26

Latest quarter to Sep 2026: revenue $25M (+25.2% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Sight Sciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$77 M
Operating income
$-37 M
Net income
$-38 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$115 M
Total liabilities
$51 M
Total equity
$64 M

As of December-2025

Top 100 institutional investors in Sight Sciences, Inc.#

As of Sep 30, 2026
131 institutions held 23.1 M shares (about 41.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Sight Sciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Long Focus Capital Management, LLC3,844,1000 (0.00%)6.92%$36 MNov 16, 2026
2BlackRock, Inc.3,361,212+278,104 (+9.02%)6.05%$31 MNov 13, 2026
3Pathstone Holdings, LLC2,186,524+507,544 (+30.23%)3.93%$20 MNov 13, 2026
4Vanguard Capital Management LLC1,635,379+61,564 (+3.91%)2.94%$15 MNov 13, 2026
5Geode Capital Management, LLC979,093+20,528 (+2.14%)1.76%$9 MNov 6, 2026
6B Group, Inc.970,0000 (0.00%)1.75%$9 MNov 16, 2026
7Acadian Asset Management LLC844,119+37,543 (+4.65%)1.52%$8 MNov 9, 2026
8State Street Corp840,635+5,183 (+0.62%)1.51%$8 MNov 12, 2026
9Millennium Management LLC709,451+634,144 (+842.08%)1.28%$7 MNov 16, 2026
10Dimensional Fund Advisors LP370,755-12,757 (-3.33%)0.67%$3 MNov 4, 2026
11Northern Trust Corp354,044+10,462 (+3.04%)0.64%$3 MNov 16, 2026
12D. E. Shaw & Co., Inc.349,051+69,102 (+24.68%)0.63%$3 MNov 16, 2026
13Charles Schwab Investment Management Inc324,254+48,701 (+17.67%)0.58%$3 MNov 16, 2026
14Panagora Asset Management Inc298,693+36,165 (+13.78%)0.54%$3 MNov 12, 2026
15Next Century Growth Investors LLC289,863New0.52%$3 MNov 13, 2026
16Jacobs Levy Equity Management, Inc283,230-55,211 (-16.31%)0.51%$3 MNov 16, 2026
17Vanguard Fiduciary Trust Co281,576+25,498 (+9.96%)0.51%$3 MNov 13, 2026
18AQR Capital Management LLC278,501-119,057 (-29.95%)0.50%$3 MNov 16, 2026
19Goldman Sachs Group Inc278,044+77,917 (+38.93%)0.50%$3 MNov 16, 2026
20Vanguard Portfolio Management LLC276,435+3,950 (+1.45%)0.50%$3 MNov 13, 2026
21Morgan Stanley215,601+60,379 (+38.90%)0.39%$2 MNov 13, 2026
22Invesco Ltd.214,173+192,899 (+906.74%)0.39%$2 MNov 12, 2026
23Qube Research & Technologies Ltd199,219-163,484 (-45.07%)0.36%$2 MNov 13, 2026
24Renaissance Technologies LLC195,858-16,800 (-7.90%)0.35%$2 MNov 12, 2026
25Lazard Asset Management LLC190,731+66,176 (+53.13%)0.34%$2 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Sight Sciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Royce & Associates LP179,043New0.32%$2 MNov 9, 2026
27Gsa Capital Partners LLP156,486-11,078 (-6.61%)0.28%$1 MNov 16, 2026
28Topline Capital Management, LLC144,372New0.26%$1 MNov 16, 2026
29Nuveen, LLC144,069+49,492 (+52.33%)0.26%$1 MNov 10, 2026
30Bank Of America Corp /de/140,076+44,043 (+45.86%)0.25%$1 MNov 16, 2026
31Palumbo Wealth Management LLC133,394+4,858 (+3.78%)0.24%$1 MNov 13, 2026
32Citadel Advisors LLC126,564-89,743 (-41.49%)0.23%$1 MNov 16, 2026
33Informed Momentum Co LLC108,956New0.20%$1 MNov 16, 2026
34Squarepoint Ops LLC102,560-115,548 (-52.98%)0.18%$1 MNov 9, 2026
35Two Sigma Investments, LP97,683+56,739 (+138.58%)0.18%$1 MNov 16, 2026
36UBS Group AG96,375-29,719 (-23.57%)0.17%$1 MNov 10, 2026
37Bank of New York Mellon Corp94,432+3,041 (+3.33%)0.17%$1 MNov 5, 2026
38XTX Topco Ltd94,041-1,726 (-1.80%)0.17%$1 MNov 16, 2026
39SCS Capital Management LLC90,0000 (0.00%)0.16%$1 MNov 12, 2026
40SEI Investments Co88,015New0.16%$1 MNov 10, 2026
41Balyasny Asset Management L.P.80,168New0.14%$1 MNov 16, 2026
42Bridgeway Capital Management, LLC76,187+10,454 (+15.90%)0.14%$1 MNov 16, 2026
43Walleye Capital LLC71,073New0.13%$1 MNov 13, 2026
44Integrated Quantitative Investments LLC67,838+32,682 (+92.96%)0.12%$1 MNov 13, 2026
45State Of Wisconsin Investment Board66,837+25,637 (+62.23%)0.12%$1 MNov 16, 2026
46Empowered Funds, LLC65,987New0.12%$1 MNov 13, 2026
47Parallel Advisors, LLC59,239-5,156 (-8.01%)0.11%$1 MNov 3, 2026
48Point72 Asset Management, L.P.54,994+38,869 (+241.05%)0.10%$1 MNov 16, 2026
49Jpmorgan Chase & Co48,786+2,558 (+5.53%)0.09%$0 MNov 12, 2026
50Prudential Financial Inc47,602New0.09%$0 MNov 16, 2026
51Rhumbline Advisers46,844-1,705 (-3.51%)0.08%$0 MNov 10, 2026
52HSBC Holdings PLC46,7070 (0.00%)0.08%$0 MNov 16, 2026
53Canada Pension Plan Investment Board46,600-8,500 (-15.43%)0.08%$0 MNov 16, 2026
54Occudo Quantitative Strategies LP41,465+16,998 (+69.47%)0.07%$0 MNov 16, 2026
55Hillsdale Investment Management Inc.39,300New0.07%$0 MNov 12, 2026
56Alliancebernstein L.P.38,8800 (0.00%)0.07%$0 MNov 16, 2026
57Barclays PLC35,990+9,408 (+35.39%)0.06%$0 MNov 6, 2026
58Foster Victor Wealth Advisors, LLC35,8950 (0.00%)0.06%$0 MOct 21, 2026
59Deutsche Bank AG\33,776-201 (-0.59%)0.06%$0 MNov 6, 2026
60Price T Rowe Associates Inc /MD/32,2940 (0.00%)0.06%$0 MNov 16, 2026
61Public Employees Retirement System Of Ohio32,139New0.06%$0 MNov 16, 2026
62Susquehanna International Group, LLP28,394New0.05%$0 MNov 16, 2026
63Ieq Capital, LLC26,635+1,803 (+7.26%)0.05%$0 MNov 10, 2026
64Algert Global LLC25,966-2,300 (-8.14%)0.05%$0 MNov 17, 2026
65MetLife Investment Management, LLC23,019-751 (-3.16%)0.04%$0 MNov 16, 2026
66Russell Investments Group, Ltd.22,563-187,598 (-89.26%)0.04%$0 MNov 6, 2026
67R Squared Ltd19,759+3,388 (+20.70%)0.04%$0 MNov 6, 2026
68Diversified Trust Co18,989+4,068 (+27.26%)0.03%$0 MNov 6, 2026
69MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.18,804+683 (+3.77%)0.03%$0 MNov 16, 2026
70Kemnay Advisory Services Inc.15,706+9,090 (+137.39%)0.03%$0 MNov 16, 2026
71Graham Capital Management, L.P.14,846-19,778 (-57.12%)0.03%$0 MNov 16, 2026
72Quadrature Capital Ltd14,794New0.03%$0 MNov 13, 2026
73Wealth Enhancement Advisory Services, LLC13,918-50 (-0.36%)0.03%$0 MOct 13, 2026
74Vanguard Global Advisers, LLC13,794+202 (+1.49%)0.02%$0 MNov 13, 2026
75Police & Firemen's Retirement System of New Jersey12,6030 (0.00%)0.02%$0 MNov 9, 2026
76WealthTrust Asset Management, LLC12,500-8,456 (-40.35%)0.02%$0 MOct 22, 2026
77Schonfeld Strategic Advisors LLC12,259New0.02%$0 MNov 16, 2026
78Creative Planning12,130New0.02%$0 MNov 2, 2026
79Wells Fargo & Company/mn11,960-23,941 (-66.69%)0.02%$0 MNov 16, 2026
80Bank Of Montreal /can/11,7550 (0.00%)0.02%$0 MNov 9, 2026
81Savant Capital, LLC11,709New0.02%$0 MNov 6, 2026
82Mariner, LLC10,933New0.02%$0 MNov 12, 2026
83Manufacturers Life Insurance Company, The10,867-226 (-2.04%)0.02%$0 MNov 13, 2026
84Principal Financial Group Inc10,845New0.02%$0 MNov 2, 2026
85Arrowstreet Capital, Limited Partnership10,788New0.02%$0 MNov 13, 2026
86Vanguard Personalized Indexing Management, LLC10,193-282 (-2.69%)0.02%$0 MNov 16, 2026
87Brevan Howard Capital Management LP10,190New0.02%$0 MNov 16, 2026
88BNP Paribas Financial Markets10,078+3,639 (+56.51%)0.02%$0 MNov 12, 2026
89New York State Common Retirement Fund8,6850 (0.00%)0.02%$0 MNov 17, 2026
90Signaturefd, LLC8,4330 (0.00%)0.02%$0 MOct 23, 2026
91FMR LLC8,144+264 (+3.35%)0.01%$0 MNov 10, 2026
92Federated Hermes, Inc.6,560+4,744 (+261.23%)0.01%$0 MNov 12, 2026
93Conquis Financial LLC5,0000 (0.00%)0.01%$0 MNov 10, 2026
94Legal & General Group Plc3,7660 (0.00%)0.01%$0 MNov 16, 2026
95Ameritas Investment Partners, Inc.3,4420 (0.00%)0.01%$0 MNov 13, 2026
96Royal Bank Of Canada3,023+124 (+4.28%)0.01%$0 MNov 16, 2026
97Arax Advisory Partners2,872+133 (+4.86%)0.01%$0 MNov 12, 2026
98UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,406+1,918 (+393.03%)0.00%$0 MNov 16, 2026
99Caldwell Sutter Capital, Inc.2,0000 (0.00%)0.00%$0 MNov 9, 2026
100Citigroup Inc1,951-16,483 (-89.42%)0.00%$0 MNov 4, 2026

All 131 institutional investors, with who bought and sold →

Mutual funds holding Sight Sciences, Inc.#

94 funds hold shares worth $31 M (about 6.7% of the company). Since their previous reports 42 added shares and 25 sold, buying $0 M net.
Mutual funds holding Sight Sciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.14 M$6 M1.3%<0.01%+8.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.03 M$6 M1.2%<0.01%+0.9%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC429,723$2 M0.50%<0.01%+3.7%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.381,573$2 M0.45%<0.01%+5.0%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors374,550$2 M0.44%0.01%+9.2%Jun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors269,592$1 M0.32%0.03%+29%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.215,532$1 M0.25%<0.01%+4.4%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC177,218$1 M0.21%<0.01%+5.6%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.163,525$1 M0.19%<0.01%−1.6%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors132,333$1 M0.16%0.05%+26%Jun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP101,539$1 M0.12%<0.01%+0.7%Jul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.92,208$0 M0.11%<0.01%+0.2%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP83,670$0 M0.10%<0.01%+5.4%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC71,563$0 M0.08%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.57,660$0 M0.07%<0.01%+333%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC64,020$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC55,533$0 M0.07%0.20%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC47,645$0 M0.06%<0.01%−1.2%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC47,057$0 M0.06%<0.01%+8.8%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC47,520$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC51,303$0 M0.06%<0.01%+4.5%May 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP43,335$0 M0.05%<0.01%+19%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC36,679$0 M0.04%0.01%+15%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.39,124$0 M0.05%0.01%+3.1%May 31, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.31,829$0 M0.04%0.03%+101%Jun 30, 2026
🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust30,000$0 M0.04%0.02%−38%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC33,203$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation27,900$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC22,390$0 M0.03%<0.01%+7.2%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.19,964$0 M0.02%<0.01%−12%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC18,531$0 M0.02%0.04%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC18,779$0 M0.02%<0.01%+2.1%Jul 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.20,000$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.17,749$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.17,683$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC18,093$0 M0.02%0.04%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC17,823$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company16,674$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.14,900$0 M0.02%<0.01%+9.6%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC14,862$0 M0.02%<0.01%+11%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC13,916$0 M0.02%<0.01%+60%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC12,918$0 M0.02%<0.01%+8.8%Jul 31, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.11,435$0 M0.01%<0.01%−6.7%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.11,168$0 M0.01%0.02%−4.5%Jun 30, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC10,907$0 M0.01%0.04%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC10,600$0 M0.01%<0.01%+16%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC10,444$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC8,919$0 M0.01%0.02%+15%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,004$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC8,346$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC8,072$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS8,068$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC7,943$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC7,402$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,330$0 M<0.01%<0.01%+18%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,056$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,993$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.5,934$0 M<0.01%<0.01%+31%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,711$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC5,287$0 M<0.01%<0.01%+2.9%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,696$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.4,080$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,161$0 M<0.01%<0.01%+25%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.4,114$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,442$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,421$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,395$0 M<0.01%<0.01%+8.1%Jul 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP3,387$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,139$0 M<0.01%<0.01%+8.1%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,207$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,054$0 M<0.01%0.01%+0.5%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC2,679$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP2,673$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation2,552$0 M<0.01%<0.01%−5.3%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC2,472$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation2,357$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC2,351$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION2,400$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,839$0 M<0.01%<0.01%−48%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,970$0 M<0.01%<0.01%+8.7%May 31, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC1,680$0 M<0.01%<0.01%−5.0%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,454$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,557$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,548$0 M<0.01%<0.01%−5.1%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,540$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,119$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,044$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC900$0 M<0.01%<0.01%−18%Jun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC845$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.781$0 M<0.01%<0.01%−35%Jun 30, 2026
🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC539$0 M<0.01%<0.01%−9.1%Jun 30, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust384$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC204$0 M<0.01%<0.01%+8.5%Jul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP10$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 94 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Sight Sciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$185 K
2 purchases, 1 insider
Sold, 12 months
$3.0 M
37 sales, 6 insiders
Net, 12 months
-$2.8 M
open market only
Insiders on file
24
since
$3.0 M-$16.7 M$0Nov 2023: bought $3.0 M (11 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $16.7 M (1 trades)Jan 2024: bought $0 (0 trades), sold $151 K (4 trades)Apr 2024: bought $0 (0 trades), sold $173 K (5 trades)May 2024: bought $0 (0 trades), sold $71 K (1 trades)MayJul 2024: bought $0 (0 trades), sold $219 K (5 trades)Oct 2024: bought $0 (0 trades), sold $697 K (9 trades)Nov 2024: bought $2.1 M (3 trades), sold $2.1 M (1 trades)Dec 2024: bought $32 K (2 trades), sold $0 (0 trades)DecJan 2025: bought $0 (0 trades), sold $233 K (9 trades)Mar 2025: bought $53 K (2 trades), sold $0 (0 trades)Apr 2025: bought $0 (0 trades), sold $148 K (5 trades)May 2025: bought $609 K (4 trades), sold $45 K (1 trades)MayJun 2025: bought $601 K (5 trades), sold $0 (0 trades)Jul 2025: bought $0 (0 trades), sold $259 K (5 trades)Oct 2025: bought $0 (0 trades), sold $201 K (5 trades)Nov 2025: bought $0 (0 trades), sold $489 K (3 trades)NovDec 2025: bought $116 K (1 trades), sold $21 K (1 trades)Jan 2026: bought $0 (0 trades), sold $877 K (16 trades)Apr 2026: bought $0 (0 trades), sold $312 K (6 trades)May 2026: bought $0 (0 trades), sold $65 K (1 trades)MayJun 2026: bought $69 K (1 trades), sold $0 (0 trades)Jul 2026: bought $0 (0 trades), sold $448 K (6 trades)Oct 2026: bought $0 (0 trades), sold $653 K (5 trades)Nov 2026: bought $0 (0 trades), sold $220 K (1 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Sight Sciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Brenton TaylorEVP, Operations & R&DSell10b5-1 plan-20,685$10.64$220 K241,305Form 4
filed James RodbergChief Financial OfficerSell10b5-1 plan-7,208$8.853$64 K216,829Form 4
filed Alison BauerleinChief Operating OfficerSell10b5-1 plan-25,260$8.853$224 K639,449Form 4
filed Brenton TaylorEVP, Operations & R&DSell10b5-1 plan-2,988$8.853$26 K261,990Form 4
filed Paul BadawiPresident and CEO, Director, 10% ownerSell10b5-1 plan-29,653$9.049$268 K6.09 MForm 4
filed David BadawiChief Technology Officer, DirectorSell10b5-1 plan-7,797$9.049$71 K1.98 MForm 4
filed Kashif RashidChief Legal OfficerGrant or award+181,818——181,818Form 4
filed David BadawiChief Technology Officer, DirectorSell10b5-1 plan-7,418$5.510$41 K1.98 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Sight Sciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.1 M
2.1% of shares · 4.31 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 9 shares at $8.38
  • : 5,220 shares at $5.64
  • : 2,210 shares at $5.53
  • : 539 shares at $5.05
  • : 13 shares at $5.46

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sight Sciences, Inc. scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in financial health (3 of 6), weakest in growth (0 of 6). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-3.1%Revenue down 3.1% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years2.7%2.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median2.7%2.7% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.74 vs -1.03Diluted EPS -0.74 in fiscal 2025 against -1.03 the year before (report's currency).
    • ✗Net income higher than five years earlier-$38 M-$38 M in fiscal 2025 against -$35 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$38 MNet income -$38 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-48.0%-48.0% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-50.8%-50.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-48.0%-48.0% in fiscal 2025 against -117.7% in 2022.
  • Financial health3 of 6
    • ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.22 at the end of fiscal 2025.
    • ✓Debt below equity0.7×Debt to equity 0.66 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $50 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-7.2×Operating income -7.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone1.23Z-score 1.23 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.0%Diluted shares up 4.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Sight Sciences, Inc.'s statements, beside the median of Medical Devices.

Sight Sciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-48.0%-8.2%
Net margin-49.7%-10.4%
Return on equity-50.8%-16.8%
Revenue growth, 3 years a year2.7%10.8%
Revenue growth-3.1%10.4%
Debt to equity0.66×0.64×

5of 9on the Piotroski tests of financial strength

  • Revenue fell 3.1% against the year before.
  • Net loss of $38 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$30 million.
  • Operating income covers the interest bill only -7.2 times.

Sight Sciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sight Sciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue778081714928
Cost of revenue111212128.69.2
Gross profit676869594018
Research and development15181823168.9
Selling, general and administrative891011091207642
General and administrative—————1.8
Operating expenses1041191261439251
Operating income−37−51−57−84−51−32
Interest and finance income—————0.0
Interest expense and finance costs5.14.75.44.54.42.4
Other non-operating income (expense)−0.1−0.0−0.0r2.2−6.9−0.1
Income before tax−38−51−55−86−63−35
Income tax0.00.20.10.00.20.1
Net income including minority interests−38−52−56−86−63−35
Net income attributable to shareholders−38−52−56−86−63−35
Earnings per share, basic-0.74-1.03-1.14-1.80-2.36-3.71
Earnings per share, diluted-0.74-1.03-1.14-1.80-2.36-3.71
Shares, weighted average (basic)5250494827—
Shares, weighted average (diluted)52504948279.4
Balance sheet
Cash and cash equivalents9212013818526162
Receivables9.71114158.75.4
Inventory7.86.37.86.13.52.6
Other current assets3.32.32.63.44.21.2
Current assets11314016321027771
Property, plant and equipment1.61.61.61.61.51.3
Right-of-use (leased) assets0.40.91.51.61.50.5
Total assets11514316721328073
Accounts payable1.31.71.72.73.42.2
Debt due within a year002.2000
Current liabilities11151218149.3
Long-term debt403932333332
Lease liabilities (non-current)00.50.90.61.00.1
Total liabilities515546534844
Retained earnings−385−346−295−239−153−90
Shareholders' equity6488120160232−89
Total liabilities and equity11514316721328073
Shares outstanding53514948489.5
Cash-flow statement
Depreciation and amortization0.50.70.6———
Share-based compensation131715135.10.5
Cash from operating activities−30−22−47−76−53−32
Capital expenditure−0.2−0.4−0.8−1.0−0.8−1.0
Cash from investing activities−0.2−0.4−0.8−1.0−0.8−1.0
Debt issued————020
Cash from financing activities1.85.01.11.225373
Change in cash−28−18−47−7619940
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Sight Sciences, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Interventional Glaucoma$76 M98%
  • Interventional Dry Eye$2 M2.1%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Sight Sciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 7 · Material agreement 2 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 12

Sight Sciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersResults announced8-K
Material agreement8-K
RestructuringDirectors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
New debtUnregistered share sale8-K
Directors and officersResults announced8-K
Results announced8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Sight Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$23 MNo. 5$10 to $50 million4equitySEC
Mar 2020$30 MNo. 4$10 to $50 million—equitySEC
Aug 2019$31 MNo. 3$10 to $50 million2equitySEC
Jul 2017$20 MNo. 2$10 to $50 million25equitySEC
Oct 2015$7 MNo. 1$2 to $10 million17equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Sight Sciences, Inc.#

$140 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.

Lobbying, 2025
$140 K
#1,122 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$20 K
  • Medicare/Medicaid3 reports

Lobbying firms hired in 2025

The McManus Group $140 K

Sight Sciences, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$20 K—1
2025$140 K—3
2024$20 K—4
2023$140 K—4
2022$240 K—7
2021$60 K—4
2020$20 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Sight Sciences” and “Sight Sciences, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Sight Sciences, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $109 K a year.

Certified, FY2026
1
#1,831 among companies on value.today
Worker positions
1
Median wage offered
$109 K
a year, full-time
Applications filed
1
Sight Sciences, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Regulatory Affairs SpecialistRegulatory Affairs Specialists1$109 K

Where: Covington, GA 1

Sight Sciences, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$109 K1
FY202511$167 K1
FY202411$107 K1
FY202322$169 K2
FY202211$98 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Sight Sciences, Inc.

FDA drug approvals: Sight Sciences, Inc.#

1 approved applications held.

Approvals held
1
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
1
0 new drugs, 0 biologics
Sight Sciences, Inc.: latest FDA approvals
ApprovedDrugKind
1996-10-18Minoxidil (For Women), Minoxidil (For Men)Minoxidil · ANDA074743Generic drug (ANDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (SIGHT PHARMS), so they follow acquisitions

Product recalls by Sight Sciences, Inc.#

1 recalls since 2015, 921 units in the notices that give a number. Medical devices (FDA): 1.

Sight Sciences, Inc.: product recalls
DateWhat and whyUnitsNotice
TearCare version 1.0 SmartHubsOphthalmic devices distributed prior to the recently-obtained 510(k) clearance do not fall within the relevant 510(k) exemption and so their performance characteristics were not evaluated by the FDA prior to distribution.Medical devicesClass II921Z-1001-2022

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Layoffs at Sight Sciences, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
25
2023–2025
Latest
—
2025-08-27
Sight Sciences, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
2023·········25··25
Sight Sciences, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
25 people (10% of workforce)Restructuring planSEC 8-K“Pursuant to the Plan, the Company intends to (a) reduce its headcount by 25 employees, or approximately 10% of its global workforce, and (b) reduce its operating expenses, principa…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Sight Sciences, Inc. compares in Medical Devices

  • Market cap$448 M · higher than 48% of 142
  • Revenue$77 M · higher than 36% of 155
  • Net margin-32.1% · higher than 31% of 144
  • Revenue growth-3.1% · higher than 14% of 104
  • Price / sales5.1× · lower than 28% of 96
  • Price / book7.0× · lower than 20% of 99
  • FCF yield-6.7% · higher than 36% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Sight Sciences, Inc.🇺🇸$448 M—-32.1%-3.1%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sight Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sight Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sight Sciences, Inc.? Suggest a correction